STRIDES PHARMA SCIENCE Financial Statement Analysis
|
||
|
The Revenues of STRIDES PHARMA SCIENCE have increased by 6.43% YoY .
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by -84.52 % YoY. |
||
STRIDES PHARMA SCIENCE Last 5 Annual Financial Results
[BOM: 532531|NSE : STAR]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹4,859 Cr | ₹4,565 Cr | ₹3,890 Cr | ₹3,688 Cr | ₹3,070 Cr |
| Expenses | ₹4,014 Cr | ₹3,768 Cr | ₹3,318 Cr | ₹3,303 Cr | ₹3,092 Cr |
| Operating Profit (Excl OI) | ₹845 Cr | ₹798 Cr | ₹572 Cr | ₹385 Cr | ₹-22 Cr |
| Other Income | ₹231 Cr | ₹64 Cr | ₹50 Cr | ₹135 Cr | ₹133 Cr |
| Interest | ₹179 Cr | ₹249 Cr | ₹280 Cr | ₹261 Cr | ₹177 Cr |
| Depreciation | ₹202 Cr | ₹192 Cr | ₹214 Cr | ₹243 Cr | ₹233 Cr |
| Profit Before Tax | ₹669 Cr | ₹487 Cr | ₹-115 Cr | ₹-286 Cr | ₹-653 Cr |
| Profit After Tax | ₹575 Cr | ₹409 Cr | ₹-144 Cr | ₹-231 Cr | ₹-474 Cr |
| Consolidated Net Profit | ₹556 Cr | ₹3,593 Cr | ₹-71 Cr | ₹-203 Cr | ₹-460 Cr |
| Earnings Per Share (Rs) | ₹60.34 | ₹389.90 | ₹-7.68 | ₹-22.44 | ₹-51.25 |
| PAT Margin (%) | 8.13 | 5.77 | -2.36 | -3.70 | -8.90 |
| ROE(%) | 20.31 | 17.52 | -6.67 | -10.15 | -18.49 |
| ROCE(%) | 18.57 | 16.56 | 3.47 | -0.49 | -9.49 |
| Total Debt/Equity(x) | 0.54 | 0.70 | 1.14 | 1.27 | 1.18 |
Key Financials |
||
| Market Cap | : | ₹ 9,285.0 Cr |
| Revenue (TTM) | : | ₹ 5,004.4 Cr |
| Net Profit(TTM) | : | ₹ 635.3 Cr |
| EPS (TTM) | : | ₹ 68.9 |
| P/E (TTM) | : | 14.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| STRIDES PHARMA SCIENCE | -2% | -6.2% | 13.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 0.5% | 14% |
| DIVIS LABORATORIES | -0.9% | 21.1% | 25.6% |
| TORRENT PHARMACEUTICALS | -1.3% | 1.1% | 32.7% |
| CIPLA | 0.2% | 2.1% | -5.1% |
| DR REDDYS LABORATORIES | 0.2% | -7.7% | -7.5% |
| MANKIND PHARMA | -1.4% | -3.7% | -5.3% |
| LUPIN | -0.7% | -5.7% | 24% |
| ZYDUS LIFESCIENCES | -0.1% | -3.9% | 14.1% |
STRIDES PHARMA SCIENCE Revenues
[BOM: 532531|NSE : STAR]
| Y-o-Y | 6.43 % |
| 5 Yr CAGR | 12.16 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,859 Cr | 6.43 | |
| Mar2025 | ₹4,565 Cr | 17.36 | |
| Mar2024 | ₹3,890 Cr | 5.47 | |
| Mar2023 | ₹3,688 Cr | 20.13 | |
| Mar2022 | ₹3,070 Cr | - | |
STRIDES PHARMA SCIENCE Operating Profit
[BOM: 532531|NSE : STAR]
| Y-o-Y | 5.86 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹845 Cr | 5.86 | |
| Mar2025 | ₹798 Cr | 39.41 | |
| Mar2024 | ₹572 Cr | 48.52 | |
| Mar2023 | ₹385 Cr | Positive | |
| Mar2022 | ₹-22 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -0.52 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 17.38% | -0.52 | |
| Mar2025 | 17.47% | 18.76 | |
| Mar2024 | 14.71% | 40.77 | |
| Mar2023 | 10.45% | Positive | |
| Mar2022 | -0.7% | - | |
STRIDES PHARMA SCIENCE Profit After Tax
[BOM: 532531|NSE : STAR]
| Y-o-Y | -84.52 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹556 Cr | -84.52 | |
| Mar2025 | ₹3,593 Cr | Positive | |
| Mar2024 | ₹-71 Cr | Negative | |
| Mar2023 | ₹-203 Cr | Negative | |
| Mar2022 | ₹-460 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 40.90 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 8.13 % | 40.90 | |
| Mar2025 | 5.77 % | Positive | |
| Mar2024 | -2.36 % | Negative | |
| Mar2023 | -3.7 % | Negative | |
| Mar2022 | -8.9 % | - | |
STRIDES PHARMA SCIENCE Earnings Per Share (EPS)
[BOM: 532531|NSE : STAR]
| Y-o-Y | -84.52 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹60 | -84.52 | |
| Mar2025 | ₹390 | Positive | |
| Mar2024 | ₹-7.68 | Negative | |
| Mar2023 | ₹-22 | Negative | |
| Mar2022 | ₹-51 | - | |
STRIDES PHARMA SCIENCE Return on Capital Employed (ROCE)
[BOM: 532531|NSE : STAR]
| Y-o-Y | 12.14 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 18.57% | 12.14 | |
| Mar2025 | 16.56% | 377.23 | |
| Mar2024 | 3.47% | Positive | |
| Mar2023 | -0.49% | Negative | |
| Mar2022 | -9.49% | - | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Current Share Price | : | ₹1,007.1 |
| Current MarketCap | : | ₹ 9,285.0 Cr |
| Updated EOD on | : | Aug 07,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | -2% |
-6.2% |
13.9% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
STRIDES PHARMA SCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | 1.3% | 3.7% | 3% |
| BSE HEALTHCARE | 0.9% | 4.1% | 11.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 3.5% | 5.6% | 8.1% |
| NIFTY SMALLCAP 500 | 2.8% | 4.7% | NA |
| NIFTY TOTAL MARKET | 1.2% | 3.6% | 3.2% |
You may also like the below Video Courses
FAQ about STRIDES PHARMA SCIENCE Financials
How the annual revenues of STRIDES PHARMA SCIENCE have changed ?
The Revenues of STRIDES PHARMA SCIENCE have increased by 6.43% YoY .
How the Earnings per Share (EPS) of STRIDES PHARMA SCIENCE have changed?
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by -84.52 % YoY .
Check out Intrinsic Value of Peers of STRIDES PHARMA SCIENCE
Compare Stock Analytics of Peers of STRIDES PHARMA SCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
